Hurvitz S, Mead M. Triple-negative breast cancer. Curr Opin Obstet Gynecol. 2015;28:1.
Article
Google Scholar
Owonikoko TK, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014.
Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728–37.
Article
CAS
PubMed
Google Scholar
Rugo HS, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL [abstract]. Cancer Res. 2013;73:Abstract nr S5_02.
Adjei AA. What is the right dose? The elusive optimal biologic dose in phase I clinical trials 1. J Clin Oncol. 2006;24:4054–5.
Article
CAS
PubMed
Google Scholar
Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010;5:1806–14.
Lankelma J, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5:1703–7.
CAS
PubMed
Google Scholar
Youk JH, Son EJ, Chung J, Kim J-A, Kim E-K. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol. 2012;22:1724–34.
Article
PubMed
Google Scholar
Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol. 2013;4:18.
Article
PubMed
PubMed Central
Google Scholar
Thurber GM, et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun. 2013;4:1504.
Article
PubMed
PubMed Central
Google Scholar
Kim ES, et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012;30:3345–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schellens JH, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer. 1996;73:1569–75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prideaux B, et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem. 2011;83:2112–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Buck A, et al. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem. 2015;407:2107–16.
Article
CAS
PubMed
Google Scholar
Salphati L, et al. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014;42:1110–6.
Article
PubMed
Google Scholar
Kimura S, et al. Development of a human mammary epithelial cell culture model for evaluation of drug transfer into milk. Arch Pharm Res. 2006;29:424–9.
Article
CAS
PubMed
Google Scholar
Yasunaga M, et al. The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. Sci Rep. 2013;3:3050.
Article
PubMed
Google Scholar
Brouwers EEM, et al. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal Bioanal Chem. 2008;391:577–85.
Article
CAS
PubMed
Google Scholar
Bonetti A, et al. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res. 1996;2:1829–35.
CAS
PubMed
Google Scholar
Williamson MJ, et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther. 2009;8:3234–43.
Article
CAS
PubMed
Google Scholar
Li X, et al. Analyzing spatial heterogeneity in DCE- and DW-MRI parametric maps to optimize prediction of pathologic response to neoadjuvant chemotherapy in breast cancer. Transl Oncol. 2014;7:14–22.
Article
PubMed
PubMed Central
Google Scholar
Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging. 1997;7:461–4.
Article
CAS
PubMed
Google Scholar
Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–767.
Daemen A, Wolf DM, Korkola JE, Griffith OL. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. 2012;505–17.
Shibata H, Miuma S, Saldivar JC, Huebner K. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. Cancer Sci. 2011;102:1882–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Palma JP, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15:7277–90.
Article
CAS
PubMed
Google Scholar
Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoSOne. 2012;7:e46614.
Article
CAS
Google Scholar
Dhawan M, et al. Differential toxicity in patients with and without DNA repair mutations: Phase I Study of carboplatin and talazoparib in advanced solid tumors. Clin Cancer Res. 2017. Forthcoming.
Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet. 2014;53:479–88.
Article
CAS
PubMed
Google Scholar
Hassan S, Esch A, Heiser L, Gray J. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer [abstract]. J Clin Oncol. 2015;33:28S. Abstract 125.
Wang B, et al. Discovery and characterization of (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, talazoparib), a novel, highly potent, and orally efficacious poly(ADP-ribose) Polymer. J Med Chem. 2016;14:335–57.
Article
Google Scholar
Muscal JA, et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010;65:419–25.
Article
CAS
PubMed
Google Scholar
Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther. 2009;85:208–11.
Article
CAS
PubMed
Google Scholar
Ekhart C, et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006;12:6502–8.
Article
CAS
PubMed
Google Scholar
Prideaux B, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015;21:1223–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huamani J, et al. Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models. Int J Radiat Oncol Biol Phys. 2008;71:237–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Atkinson SJ, Loadman PM, Sutton C, Patterson LH, Clench MR. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:1271–6.
Article
CAS
PubMed
Google Scholar
Reiner T, et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia. 2012;14:169–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.
Article
CAS
PubMed
Google Scholar
Nel I, et al. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer. 2013;109:1223–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jarvis IWH, et al. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochem Pharmacol. 2012;83:69–77.
Article
CAS
PubMed
Google Scholar
Liedert B, Pluim D, Schellens J, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 2006;34:e47.
Article
PubMed
PubMed Central
Google Scholar
Zivanovic O, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136:699–708.
CAS
PubMed
Google Scholar
Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–20.
Article
CAS
PubMed
Google Scholar
Li M, Yu X. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene. 2014.
Kummar S, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27:2705–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
LoRusso PM, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res. 2016;22:3227–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murray J, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110:1977–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murai J, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13:433–43.
Article
CAS
PubMed
Google Scholar
Murai J, Huang SN, Das BB. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. 2012:5588–99.
Johnson N, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci. 2013;110:17041–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Somlo G, et al. Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII. J Clin Oncol. 2014;32:1021.
Google Scholar
Han H, et al. Efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs. placebo in patients with BRCA1 or BRCA2 mutations in metastatic breast cancer. A randomized phase 2 study [abstract]. San Antonio Breast Cancer Symposium. 2016. Abstract S2-05.
Robson ME, suppl, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) [abstract]. J Clin Oncol. 2017;35:abstract LBA4.
Geyer CE, et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC) [abstract]. J Clin Oncol. 2017;35, ASCO, abstract Suppl 205.
Olaussen KA, et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer. 2013;80:216–22.
Article
PubMed
Google Scholar
Palma JP, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res. 2008;28:2625–35.
CAS
PubMed
Google Scholar
Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos. 2011;39:1161–9.
Article
CAS
PubMed
Google Scholar
Daemen A, et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat. 2012;135:505–17.
Kao J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4:e6146.
Lau Y-KI, et al. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 2014;5:10503–17.
Kikuchi R, et al. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci. 2013;102:4426–32.
Birkbak NJ, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011;71:3447–52.
Lin F, et al. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014;20:2703–13.
Sarathy JP, et al. Prediction of drug penetration in tuberculosis lesions. ACS Infect Dis. 2016;2:552–63.
Chen J-H, et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol. 2007;18:2042–3.
Schmitz AMT, Loo CE, Wesseling J, Pijnappel RM, Gilhuijs KGA. Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype. Breast Cancer Res Treat. 2014;148:541–51.
Teifke A, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology. 2006;239:351–60.
Arjaans M, et al. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2015;7:21247–58.
Knight JC, Koustoulidou S, Cornelissen B. Imaging the DNA damage response with PET and SPECT. Eur J Nucl Med Mol Imaging. 2017;44:1065–78.
Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479–85.
Martelotto L, Ng C, Piscuoglio S, Weigelt B, Reis-Filho J. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014;15:1–11.
Fu F, Nowak MA, Bonhoeffer S. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol. 2015;11:e1004142.